Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL productsEleni Kotsiou, Katy Newton, Shreenal Patel et al.|Cancer Research|2020Cited by 3
Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical useHenrieta Fraser, Edward Samuel, Rebecca Pike et al.|Cancer Research|2020Cited by 0
Next generation clonal neoantigen targeting T cells, generated using the PELEUS (TM) bioinformatics platform and the VELOS (TM) manufacturing method show superior reactivity and phenotypic characteristics than classical TIL productsEleni Kotsiou, Katy Newton, Tz Hou et al.|UCL Discovery (University College London)|2020Cited by 0